Stomach Diseases  >>  cisplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

19 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT01461057 / 2011-002331-25: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Checkmark ESMO-ECCO-ESTRO 2013
Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013
Completed
2a
30
Europe, RoW
Capecitabine, Xeloda, Cisplatin, Pertuzumab, Perjeta, Trastuzumab, Herceptin
Hoffmann-La Roche
Gastric Cancer
03/15
10/17
NCT00042510: Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

Completed
2
103
US
Treatment group
Cancer Advances Inc.
Stomach Neoplasms, Esophageal Neoplasms
02/03
07/04
NCT00165464: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Completed
2
54
US
Taxotere, Cisplatin, Irinotecan
Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Aventis Pharmaceuticals
Esophageal Cancer, Gastric Cancer, GE Junction Cancer
03/05
04/09
NCT00190801: Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma

Completed
2
50
RoW
pemetrexed, cisplatin
Eli Lilly and Company
Gastrointestinal Neoplasms
 
09/05
NCT00215995: Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Completed
2
21
US
Cisplatin, Platinol, Platinol-AQ, Irinotecan, Camptosar, ZD 1839, Iressa
H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca
Esophageal Cancer, Gastric Cancer
05/07
05/07
NCT00394433: Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Completed
2
38
US
Bevacizumab, Avastin, Docetaxel, Taxotere, Docefrez, Cisplatin, Platinol-AQ, Platinol, Irinotecan, Camptosar
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc.
Esophageal Cancer, Stomach Cancer
11/08
10/16
EXTRA, NCT00477711: A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer

Checkmark In combination with cisplatin & capecitabine in adv gastric or esophagogastric junction adenocarcinoma
Sep 2014 - Sep 2014: In combination with cisplatin & capecitabine in adv gastric or esophagogastric junction adenocarcinoma
Completed
2
41
RoW
cetuximab, cisplatin, capecitabine
Peking University, Merck Sharp & Dohme LLC
Gastric Cancer
12/08
02/09
NCT00415168: Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Completed
2
53
RoW
pemetrexed, LY231514, Alimta, cisplatin
Eli Lilly and Company
Gastric Cancer
07/09
07/09
NCT00454636 / 2006-004512-43: A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Completed
2
158
Europe
Cisplatin, Capecitabine, Xeloda, Epirubicin, Oxaliplatin, Docetaxel
Hoffmann-La Roche
Gastric Cancer
07/10
07/10
NCT00857246: Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Completed
2
30
US
Cetuximab, Erbitux, Irinotecan, CPT-11, Camptosar, Cisplatin, Platinol-AQ, Surgery, 5-FU, Fluorourocil, Radiation
NYU Langone Health, Bristol-Myers Squibb, Eli Lilly and Company
Gastric Cancer, Stomach Cancer
09/11
10/15
NCT00952497 / 2009-010730-21: A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

Completed
2
48
US, Europe
Cisplatin, Capecitabine, Telatinib
ACT Biotech, Inc
Gastric Cancer
10/11
01/12
NCT00390416: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Completed
2
48
US
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Memorial Sloan Kettering Cancer Center, Sanofi, Genentech, Inc.
Stomach Neoplasms, Esophageal Neoplasms
01/12
01/12
NEOTAX, NCT00343239: Docetaxel in Locally Advanced Gastric Adenocarcinoma

Completed
2
59
RoW
Docetaxel, Cisplatin, Fluorouracil
Sanofi
Stomach Neoplasms
03/12
03/12
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
22
US
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University
Esophageal Cancer, Gastric Cancer
02/15
02/15
NEOPECX, NCT01234324 / 2008-007798-18: ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction

Completed
2
171
Europe
Epirubicin, Cisplatin, Capecitabine, Panitumumab, Xeloda®, Epirubicin, Cisplatin, Capecitabine, Vectibix®, Xeloda®
AIO-Studien-gGmbH, Amgen, WiSP Wissenschaftlicher Service Pharma GmbH
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
08/16
08/17
NCT00719550 / 2008-001605-42: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Checkmark As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Jun 2014 - Jun 2014: As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark
More
Completed
1b/2
130
US, Canada, Europe, RoW
Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo
Amgen
Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
11/10
06/13
NCT00320515: Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer

Completed
1/2
89
RoW
pemetrexed, LY231514, Alimta, cisplatin
Eli Lilly and Company
Neoplasm, Gastric
07/08
07/08
NCT01355302 / 2011-000774-58: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Terminated
1/2
7
US, Europe, RoW
E7050, cisplatin, capecitabine
Eisai Inc., Quintiles, Inc.
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
04/13
07/13
NCT01783951: Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Completed
1/2
63
RoW
DC-CIK, S-1, Cisplatin
Capital Medical University, Duke University, Geneplus-Beijing Co. Ltd.
Gastric Cancer
02/18
06/18

Download Options